Floatz Rating
CC47/100
Confidence
Indicative
Sponsor
iN Therapeutics Co., Ltd.
Modality
UNKNOWN
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
32Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06218784CT.gov A MAD Study to Evaluate the Safety, Tolerability and PK/PD of iN1011-N17 in Healthy Volunteers and PHN Patients. | — | Recruiting | — | — | — |
NCT05496205CT.gov A SAD Study to Evaluate the Safety, Tolerability and PK/PD of iN1011-N17 in Healthy Volunteers | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95Moderate confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Postherpetic Neuralgia
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| in1011-n17 (this asset) | iN Therapeutics Co., Ltd. | P1 | CC · 47 |
| Lidocaine | Seoul National University Hospital | P4 | BBB |
| Pregabalin | Neurodawn Pharmaceutical Co., Ltd. | P4 | BBB |
| Gabapentin | University of Medicine and Pharmacy at Ho Chi Minh City | P4 | BBB |
| Capsaicin | Astellas Pharma Europe Ltd. | P4 | BBB |
| Crisugabalin | Haisco Pharmaceutical Group Co., Ltd. | P3 | BB |
| (±)-Tramadol | Astellas Pharma Inc | P4 | BB |
| Marcaine | Shirong Tan | P4 | BB |
| Eslicarbazepine Acetate | Bial - Portela C S.A. | P3 | BB |
+42 more in the Postherpetic Neuralgia cohort
Other indications for in1011-n17
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Osteoarthritis | — | P1 | CC · 46 |
| Neuralgia | — | P1 | CC · 42 |
| Chronic Pain Syndrome | — | P1 | CC · 42 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. in1011-n17 in Postherpetic Neuralgia. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/in1011-n17-postherpetic-neuralgia
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →